| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $10.9M | +8.8% |
| R&D Expense | $38.6M | -2.4% |
| SG&A Expense | $16.8M | -10.0% |
| Operating Income | -$44.5M | +7.8% |
| Net Income | -$43.4M | +8.5% |
| EPS (Basic) | -$6.88 | +23.2% |
| EPS (Diluted) | -$6.88 | +23.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $20.0M | -25.1% |
| Short-term Investments | $0 | -100.0% |
| Accounts Receivable | $3.3M | +19.9% |
| Current Assets | $26.4M | -56.7% |
| Total Assets | $41.3M | -46.6% |
| Current Liabilities | $19.0M | +40.8% |
| Total Liabilities | $47.3M | -18.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$39.6M | -2.9% |
| Investing Cash Flow | $29.4M | -22.1% |
| Financing Cash Flow | $3.4M | -54.7% |
| Stockholders' Equity |
| -$6.0M |
| -130.5% |